Symyx Technologies, Inc. announced that the latest release of the Symyx Metabolite database is now available via the Symyx Isentris data access, analysis, and decision support system, as well as the Web-based DiscoveryGate content platform.
   
With Isentris, pharmacologists and medicinal chemists can now explore metabolic biotransformation pathways in ways previously not possible, according to Symyx. Combining in-house and Symyx Metabolite data, scientists are free to navigate through possible biotransformation routes generated from known metabolites, intermediates, and their known transformations.
 
As biotransformation pathways are explored, Isentris also informs scientists if there are additional toxic, physicochemical, or biological properties known about the metabolites and their intermediates. Scientists can drill down to related molecule information to further explore and report on possible adverse effects or properties as a result of metabolism.
   
Symyx Metabolite provides comprehensive coverage of xenobiotic transformations and metabolic schemes from respected published sources, as well as non-proprietary metabolism studies from new drug applications published by the US Food and Drug Administration. This information helps researchers better understand degradation pathways of known compounds within humans and lab animals.
 
www.symyx.com